| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 37 | 2023 | 2220 | 3.030 |
Why?
|
| Pacemaker, Artificial | 4 | 2020 | 105 | 1.960 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 18 | 2018 | 968 | 1.940 |
Why?
|
| Hospitals, Veterans | 7 | 2020 | 246 | 1.890 |
Why?
|
| Skilled Nursing Facilities | 3 | 2020 | 122 | 1.840 |
Why?
|
| United States Department of Veterans Affairs | 13 | 2021 | 555 | 1.680 |
Why?
|
| Percutaneous Coronary Intervention | 11 | 2021 | 455 | 1.620 |
Why?
|
| Prosthesis-Related Infections | 4 | 2020 | 73 | 1.550 |
Why?
|
| Transitional Care | 2 | 2020 | 38 | 1.370 |
Why?
|
| Multiple Pulmonary Nodules | 3 | 2023 | 26 | 1.300 |
Why?
|
| Veterans | 12 | 2020 | 1208 | 1.260 |
Why?
|
| Subacute Care | 2 | 2019 | 74 | 1.240 |
Why?
|
| Myocardial Infarction | 9 | 2018 | 968 | 1.160 |
Why?
|
| Patient Discharge | 5 | 2020 | 796 | 1.100 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2023 | 26 | 1.100 |
Why?
|
| Aged | 69 | 2024 | 19657 | 1.090 |
Why?
|
| Defibrillators, Implantable | 2 | 2020 | 299 | 1.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 7 | 2013 | 229 | 0.970 |
Why?
|
| Coronary Artery Disease | 8 | 2021 | 647 | 0.960 |
Why?
|
| Middle Aged | 74 | 2021 | 27617 | 0.940 |
Why?
|
| Pyrazoles | 5 | 2013 | 363 | 0.920 |
Why?
|
| Male | 103 | 2024 | 57801 | 0.900 |
Why?
|
| Female | 105 | 2024 | 61564 | 0.870 |
Why?
|
| United States | 33 | 2021 | 12555 | 0.840 |
Why?
|
| Pyridines | 4 | 2013 | 440 | 0.830 |
Why?
|
| Cardiac Catheterization | 6 | 2020 | 541 | 0.810 |
Why?
|
| Quinazolines | 6 | 2008 | 245 | 0.780 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2019 | 100 | 0.780 |
Why?
|
| Retrospective Studies | 33 | 2021 | 12978 | 0.740 |
Why?
|
| Heart Failure | 5 | 2024 | 1969 | 0.740 |
Why?
|
| Humans | 132 | 2024 | 118972 | 0.730 |
Why?
|
| Antineoplastic Agents | 11 | 2013 | 1974 | 0.720 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2019 | 1200 | 0.700 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2018 | 610 | 0.690 |
Why?
|
| Risk Factors | 31 | 2023 | 9000 | 0.690 |
Why?
|
| Surgical Wound Infection | 2 | 2020 | 251 | 0.660 |
Why?
|
| Myocardial Ischemia | 2 | 2019 | 251 | 0.650 |
Why?
|
| Mucin 5AC | 1 | 2018 | 46 | 0.650 |
Why?
|
| Ventricular Function, Right | 1 | 2020 | 257 | 0.640 |
Why?
|
| Stroke Volume | 2 | 2020 | 512 | 0.640 |
Why?
|
| Survival Analysis | 9 | 2020 | 1267 | 0.640 |
Why?
|
| Adenocarcinoma | 7 | 2017 | 812 | 0.630 |
Why?
|
| Clostridium Infections | 1 | 2018 | 57 | 0.630 |
Why?
|
| ErbB Receptors | 7 | 2018 | 569 | 0.620 |
Why?
|
| Electronic Health Records | 3 | 2020 | 829 | 0.620 |
Why?
|
| Vancomycin | 1 | 2018 | 79 | 0.620 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2018 | 811 | 0.610 |
Why?
|
| Palliative Care | 2 | 2024 | 629 | 0.610 |
Why?
|
| Patient Readmission | 6 | 2020 | 634 | 0.590 |
Why?
|
| Carcinogenesis | 1 | 2018 | 182 | 0.590 |
Why?
|
| Nevus, Pigmented | 2 | 2014 | 33 | 0.590 |
Why?
|
| Population Surveillance | 1 | 2020 | 413 | 0.580 |
Why?
|
| Biomarkers, Tumor | 9 | 2018 | 1059 | 0.580 |
Why?
|
| Quality Assurance, Health Care | 2 | 2017 | 325 | 0.570 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 402 | 0.560 |
Why?
|
| Melanosis | 2 | 2014 | 14 | 0.540 |
Why?
|
| Medication Errors | 1 | 2016 | 92 | 0.530 |
Why?
|
| Risk Assessment | 8 | 2021 | 3057 | 0.530 |
Why?
|
| Follow-Up Studies | 18 | 2022 | 4596 | 0.520 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2024 | 464 | 0.520 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 215 | 0.520 |
Why?
|
| Heart Ventricles | 1 | 2020 | 727 | 0.520 |
Why?
|
| Albinism, Oculocutaneous | 1 | 2014 | 6 | 0.520 |
Why?
|
| Medicare | 5 | 2021 | 663 | 0.520 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 6561 | 0.520 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2024 | 1137 | 0.510 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2014 | 24 | 0.510 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 709 | 0.510 |
Why?
|
| Time Factors | 14 | 2020 | 6412 | 0.500 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 151 | 0.500 |
Why?
|
| Cohort Studies | 20 | 2023 | 5116 | 0.500 |
Why?
|
| Specialization | 1 | 2015 | 120 | 0.490 |
Why?
|
| Antimicrobial Stewardship | 1 | 2016 | 95 | 0.490 |
Why?
|
| Glutamates | 2 | 2013 | 60 | 0.490 |
Why?
|
| Guanine | 2 | 2013 | 75 | 0.480 |
Why?
|
| Algorithms | 3 | 2020 | 1541 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1244 | 0.470 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 227 | 0.460 |
Why?
|
| End Stage Liver Disease | 1 | 2014 | 73 | 0.460 |
Why?
|
| Telemedicine | 2 | 2024 | 664 | 0.460 |
Why?
|
| Autoimmunity | 6 | 2019 | 831 | 0.450 |
Why?
|
| Exercise Test | 2 | 2015 | 551 | 0.450 |
Why?
|
| Sputum | 3 | 2012 | 290 | 0.450 |
Why?
|
| Incidence | 13 | 2018 | 2424 | 0.450 |
Why?
|
| Parkinson Disease | 3 | 2012 | 334 | 0.440 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 1510 | 0.430 |
Why?
|
| Prognosis | 11 | 2020 | 3443 | 0.430 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 222 | 0.420 |
Why?
|
| Reoperation | 1 | 2014 | 557 | 0.420 |
Why?
|
| Tissue Donors | 1 | 2014 | 336 | 0.420 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 360 | 0.420 |
Why?
|
| Survivors | 1 | 2015 | 418 | 0.420 |
Why?
|
| Databases, Factual | 9 | 2020 | 1231 | 0.420 |
Why?
|
| Hepatitis C | 1 | 2014 | 217 | 0.410 |
Why?
|
| Mortality | 6 | 2020 | 299 | 0.410 |
Why?
|
| Quality of Life | 4 | 2024 | 2366 | 0.410 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 683 | 0.400 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2016 | 310 | 0.390 |
Why?
|
| Treatment Outcome | 19 | 2021 | 9342 | 0.380 |
Why?
|
| Lung | 7 | 2020 | 3664 | 0.380 |
Why?
|
| Hypertension, Pulmonary | 5 | 2020 | 1794 | 0.380 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 965 | 0.370 |
Why?
|
| Islets of Langerhans | 5 | 2019 | 739 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2017 | 1390 | 0.370 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2020 | 842 | 0.360 |
Why?
|
| Physical Therapy Modalities | 3 | 2012 | 274 | 0.350 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 1125 | 0.340 |
Why?
|
| Glutens | 2 | 2019 | 56 | 0.340 |
Why?
|
| Viremia | 1 | 2009 | 132 | 0.340 |
Why?
|
| Gene Rearrangement | 6 | 2017 | 141 | 0.330 |
Why?
|
| Skin Neoplasms | 6 | 2018 | 762 | 0.330 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2018 | 618 | 0.330 |
Why?
|
| Adaptive Immunity | 1 | 2009 | 161 | 0.330 |
Why?
|
| Veterans Health | 3 | 2019 | 167 | 0.330 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 89 | 0.330 |
Why?
|
| Breast Neoplasms | 5 | 2015 | 1965 | 0.320 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 2674 | 0.310 |
Why?
|
| Cytomegalovirus Infections | 1 | 2009 | 187 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 1167 | 0.310 |
Why?
|
| Medicaid | 3 | 2021 | 411 | 0.300 |
Why?
|
| Carcinoma, Small Cell | 1 | 2008 | 158 | 0.300 |
Why?
|
| Stroke | 5 | 2018 | 1047 | 0.300 |
Why?
|
| Patient Care Team | 2 | 2024 | 521 | 0.300 |
Why?
|
| Liver Transplantation | 1 | 2014 | 847 | 0.290 |
Why?
|
| Adult | 35 | 2024 | 31512 | 0.290 |
Why?
|
| Primary Health Care | 1 | 2016 | 1560 | 0.280 |
Why?
|
| Postoperative Complications | 3 | 2020 | 2235 | 0.280 |
Why?
|
| Sunburn | 2 | 2018 | 25 | 0.280 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2009 | 540 | 0.270 |
Why?
|
| Accidental Falls | 2 | 2018 | 154 | 0.270 |
Why?
|
| Hospitalization | 5 | 2019 | 1785 | 0.270 |
Why?
|
| Secondary Prevention | 2 | 2019 | 227 | 0.270 |
Why?
|
| Quality Improvement | 3 | 2018 | 963 | 0.270 |
Why?
|
| Disease Progression | 12 | 2019 | 2490 | 0.270 |
Why?
|
| Erythropoietin | 1 | 2006 | 82 | 0.270 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2018 | 237 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 1 | 9 | 2019 | 3360 | 0.260 |
Why?
|
| Ultraviolet Rays | 3 | 2018 | 381 | 0.260 |
Why?
|
| Program Evaluation | 3 | 2018 | 845 | 0.260 |
Why?
|
| Celiac Disease | 2 | 2019 | 267 | 0.260 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2020 | 84 | 0.260 |
Why?
|
| Retinopathy of Prematurity | 1 | 2006 | 111 | 0.250 |
Why?
|
| Mutation | 7 | 2018 | 3457 | 0.250 |
Why?
|
| Andropause | 2 | 2014 | 7 | 0.240 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 195 | 0.240 |
Why?
|
| Lung Diseases | 3 | 2024 | 718 | 0.240 |
Why?
|
| Lower Extremity | 2 | 2018 | 335 | 0.240 |
Why?
|
| Immunity, Innate | 1 | 2009 | 745 | 0.240 |
Why?
|
| Oncogenes | 2 | 2016 | 111 | 0.240 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2020 | 589 | 0.230 |
Why?
|
| Cell Proliferation | 4 | 2018 | 2275 | 0.230 |
Why?
|
| Acute Coronary Syndrome | 2 | 2018 | 257 | 0.220 |
Why?
|
| Nevus | 3 | 2018 | 25 | 0.220 |
Why?
|
| Precancerous Conditions | 3 | 2020 | 160 | 0.210 |
Why?
|
| Erythrocyte Membrane | 2 | 2015 | 52 | 0.200 |
Why?
|
| Neoplasms, Experimental | 2 | 2018 | 158 | 0.200 |
Why?
|
| Gene Dosage | 2 | 2016 | 136 | 0.200 |
Why?
|
| Diet | 5 | 2019 | 1153 | 0.190 |
Why?
|
| Prospective Studies | 7 | 2023 | 6471 | 0.190 |
Why?
|
| Medication Adherence | 3 | 2014 | 556 | 0.190 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2015 | 125 | 0.190 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 525 | 0.190 |
Why?
|
| ras Proteins | 3 | 2012 | 141 | 0.190 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2020 | 46 | 0.190 |
Why?
|
| Testosterone | 2 | 2014 | 351 | 0.180 |
Why?
|
| Hospitals, Community | 1 | 2020 | 49 | 0.180 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 82 | 0.180 |
Why?
|
| Carcinoma | 1 | 2021 | 204 | 0.180 |
Why?
|
| Smoking | 4 | 2019 | 1487 | 0.180 |
Why?
|
| Cadherins | 3 | 2006 | 186 | 0.180 |
Why?
|
| Melanoma | 4 | 2012 | 664 | 0.180 |
Why?
|
| Autoantibodies | 4 | 2019 | 1335 | 0.180 |
Why?
|
| Datasets as Topic | 1 | 2020 | 103 | 0.180 |
Why?
|
| Episode of Care | 1 | 2019 | 5 | 0.180 |
Why?
|
| Longitudinal Studies | 10 | 2019 | 2513 | 0.180 |
Why?
|
| Patient Identification Systems | 1 | 2019 | 19 | 0.180 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 160 | 0.170 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 109 | 0.170 |
Why?
|
| Critical Pathways | 1 | 2020 | 79 | 0.170 |
Why?
|
| Fluid Therapy | 1 | 2020 | 130 | 0.170 |
Why?
|
| Fee-for-Service Plans | 1 | 2019 | 79 | 0.170 |
Why?
|
| Activities of Daily Living | 2 | 2012 | 354 | 0.170 |
Why?
|
| Vascular Resistance | 1 | 2020 | 356 | 0.170 |
Why?
|
| Perioperative Care | 1 | 2020 | 132 | 0.170 |
Why?
|
| Survival Rate | 5 | 2017 | 1720 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 2174 | 0.170 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1864 | 0.170 |
Why?
|
| Oncogene Proteins | 1 | 2018 | 52 | 0.160 |
Why?
|
| Retirement | 1 | 2018 | 29 | 0.160 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 126 | 0.160 |
Why?
|
| Dietary Proteins | 1 | 2019 | 130 | 0.160 |
Why?
|
| Histamine H2 Antagonists | 1 | 2018 | 31 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 71 | 0.160 |
Why?
|
| Manufacturing Industry | 1 | 2017 | 5 | 0.160 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2018 | 74 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1440 | 0.160 |
Why?
|
| Coronary Artery Bypass | 1 | 2019 | 209 | 0.160 |
Why?
|
| Drug Users | 1 | 2018 | 39 | 0.160 |
Why?
|
| Accidents, Occupational | 1 | 2017 | 14 | 0.160 |
Why?
|
| Validation Studies as Topic | 1 | 2017 | 21 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 248 | 0.160 |
Why?
|
| Brain Neoplasms | 3 | 2015 | 1022 | 0.160 |
Why?
|
| Health Care Sector | 1 | 2017 | 26 | 0.160 |
Why?
|
| Genotype | 4 | 2017 | 1882 | 0.160 |
Why?
|
| Homeodomain Proteins | 4 | 2009 | 468 | 0.160 |
Why?
|
| Echocardiography | 1 | 2020 | 556 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 2436 | 0.160 |
Why?
|
| Transportation | 1 | 2017 | 42 | 0.160 |
Why?
|
| Reminder Systems | 1 | 2019 | 163 | 0.150 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 77 | 0.150 |
Why?
|
| Atherectomy, Coronary | 1 | 2017 | 11 | 0.150 |
Why?
|
| Thromboembolism | 1 | 2018 | 99 | 0.150 |
Why?
|
| Patient Transfer | 1 | 2019 | 143 | 0.150 |
Why?
|
| MicroRNAs | 2 | 2015 | 637 | 0.150 |
Why?
|
| Coronary Vessels | 1 | 2019 | 233 | 0.150 |
Why?
|
| Comorbidity | 3 | 2018 | 1527 | 0.150 |
Why?
|
| Contrast Media | 1 | 2020 | 373 | 0.150 |
Why?
|
| Cardiac Output | 1 | 2017 | 147 | 0.150 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 2025 | 0.150 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 1223 | 0.150 |
Why?
|
| Occupational Injuries | 1 | 2017 | 50 | 0.150 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 107 | 0.150 |
Why?
|
| Chromosome Aberrations | 1 | 2017 | 136 | 0.150 |
Why?
|
| Beryllium | 1 | 2018 | 151 | 0.150 |
Why?
|
| Odds Ratio | 2 | 2019 | 996 | 0.150 |
Why?
|
| Colorado | 11 | 2019 | 4196 | 0.140 |
Why?
|
| Pemetrexed | 2 | 2013 | 27 | 0.140 |
Why?
|
| Home Care Services | 1 | 2019 | 217 | 0.140 |
Why?
|
| Contraindications | 1 | 2016 | 86 | 0.140 |
Why?
|
| Eating | 1 | 2019 | 369 | 0.140 |
Why?
|
| Drug Labeling | 1 | 2016 | 45 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2018 | 347 | 0.140 |
Why?
|
| HLA-DQ Antigens | 1 | 2017 | 176 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2020 | 636 | 0.140 |
Why?
|
| Drug Utilization Review | 1 | 2016 | 60 | 0.140 |
Why?
|
| Advance Care Planning | 1 | 2019 | 191 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 238 | 0.140 |
Why?
|
| Berylliosis | 1 | 2018 | 183 | 0.140 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2006 | 189 | 0.140 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2016 | 69 | 0.140 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2016 | 98 | 0.140 |
Why?
|
| HLA-DR Antigens | 1 | 2017 | 224 | 0.140 |
Why?
|
| Bronchi | 2 | 2018 | 242 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2016 | 69 | 0.140 |
Why?
|
| Child | 16 | 2019 | 19129 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 336 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2019 | 537 | 0.130 |
Why?
|
| Research Report | 1 | 2016 | 75 | 0.130 |
Why?
|
| Vascular Calcification | 1 | 2017 | 123 | 0.130 |
Why?
|
| Logistic Models | 3 | 2016 | 1901 | 0.130 |
Why?
|
| Triage | 1 | 2017 | 203 | 0.130 |
Why?
|
| Device Removal | 1 | 2016 | 127 | 0.130 |
Why?
|
| Age Factors | 4 | 2018 | 2995 | 0.130 |
Why?
|
| Taxoids | 3 | 2005 | 98 | 0.130 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 544 | 0.130 |
Why?
|
| Guideline Adherence | 2 | 2019 | 523 | 0.130 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 15 | 0.130 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 649 | 0.130 |
Why?
|
| Hemorrhage | 2 | 2016 | 623 | 0.130 |
Why?
|
| Biomarkers | 3 | 2022 | 3588 | 0.120 |
Why?
|
| Health Personnel | 1 | 2020 | 588 | 0.120 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 276 | 0.120 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 88 | 0.120 |
Why?
|
| Wounds and Injuries | 3 | 2018 | 772 | 0.120 |
Why?
|
| Sex Characteristics | 2 | 2017 | 671 | 0.120 |
Why?
|
| beta-Alanine | 1 | 2014 | 20 | 0.120 |
Why?
|
| Indians, North American | 3 | 2009 | 598 | 0.120 |
Why?
|
| Gene Expression Profiling | 5 | 2008 | 1597 | 0.120 |
Why?
|
| Neuropilin-2 | 1 | 2013 | 3 | 0.120 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 1474 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 189 | 0.120 |
Why?
|
| Antithrombins | 1 | 2014 | 51 | 0.120 |
Why?
|
| Vascular Surgical Procedures | 1 | 2016 | 262 | 0.120 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2874 | 0.120 |
Why?
|
| Astrocytoma | 1 | 2014 | 113 | 0.120 |
Why?
|
| Sulindac | 2 | 2004 | 18 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 1185 | 0.120 |
Why?
|
| Mice | 8 | 2018 | 15520 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 900 | 0.120 |
Why?
|
| Stem Cells | 1 | 2018 | 559 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 398 | 0.120 |
Why?
|
| Weight Loss | 2 | 2020 | 655 | 0.110 |
Why?
|
| Coronary Angiography | 4 | 2020 | 311 | 0.110 |
Why?
|
| Cause of Death | 1 | 2015 | 380 | 0.110 |
Why?
|
| Medical Oncology | 1 | 2015 | 229 | 0.110 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 127 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2019 | 1636 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 4 | 2013 | 874 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2014 | 140 | 0.110 |
Why?
|
| Patient Safety | 1 | 2016 | 281 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2006 | 1085 | 0.110 |
Why?
|
| Sex Factors | 3 | 2014 | 1781 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 709 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 287 | 0.110 |
Why?
|
| Sunscreening Agents | 1 | 2012 | 16 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 265 | 0.110 |
Why?
|
| Iloprost | 1 | 2012 | 46 | 0.110 |
Why?
|
| Mice, Nude | 3 | 2013 | 663 | 0.110 |
Why?
|
| Waiting Lists | 1 | 2014 | 228 | 0.110 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 164 | 0.110 |
Why?
|
| Child, Preschool | 10 | 2019 | 9491 | 0.110 |
Why?
|
| DNA, Neoplasm | 3 | 2011 | 154 | 0.110 |
Why?
|
| Patient Selection | 1 | 2016 | 676 | 0.110 |
Why?
|
| Skin Aging | 1 | 2012 | 20 | 0.110 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 93 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2013 | 352 | 0.100 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2012 | 53 | 0.100 |
Why?
|
| Blood Glucose | 4 | 2020 | 1939 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 176 | 0.100 |
Why?
|
| Biopsy | 4 | 2018 | 1079 | 0.100 |
Why?
|
| Infant | 8 | 2019 | 8293 | 0.100 |
Why?
|
| Length of Stay | 1 | 2016 | 1032 | 0.100 |
Why?
|
| Photography | 1 | 2012 | 93 | 0.100 |
Why?
|
| Calcifediol | 1 | 2011 | 29 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2013 | 2851 | 0.100 |
Why?
|
| Sunlight | 1 | 2012 | 60 | 0.100 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 14 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1868 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2021 | 3171 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2016 | 654 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 969 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2014 | 555 | 0.100 |
Why?
|
| Peptides | 1 | 2016 | 879 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 2275 | 0.090 |
Why?
|
| Phenotype | 3 | 2014 | 3003 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 3 | 2011 | 1012 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 180 | 0.090 |
Why?
|
| Transplantation, Heterologous | 2 | 2009 | 194 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2007 | 1945 | 0.090 |
Why?
|
| Personality Inventory | 1 | 1990 | 134 | 0.090 |
Why?
|
| Factor Analysis, Statistical | 1 | 2010 | 270 | 0.090 |
Why?
|
| Observer Variation | 1 | 2010 | 309 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 1284 | 0.090 |
Why?
|
| Obesity | 3 | 2020 | 2746 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 162 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 4708 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 490 | 0.090 |
Why?
|
| Pregnancy in Diabetics | 1 | 1990 | 88 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 699 | 0.080 |
Why?
|
| Animals | 9 | 2018 | 33381 | 0.080 |
Why?
|
| Risk | 5 | 2013 | 853 | 0.080 |
Why?
|
| Adolescent | 12 | 2019 | 18480 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2024 | 269 | 0.080 |
Why?
|
| Apoptosis | 6 | 2012 | 2484 | 0.080 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2008 | 9 | 0.080 |
Why?
|
| Glycemic Index | 1 | 2008 | 24 | 0.080 |
Why?
|
| Exercise Therapy | 1 | 2012 | 355 | 0.080 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2008 | 49 | 0.080 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 82 | 0.080 |
Why?
|
| Cell Cycle | 3 | 2006 | 550 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1798 | 0.080 |
Why?
|
| Fluorouracil | 1 | 2008 | 151 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 354 | 0.080 |
Why?
|
| Receptors, Calcitriol | 1 | 2008 | 56 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2008 | 136 | 0.080 |
Why?
|
| Cluster Analysis | 2 | 2006 | 481 | 0.080 |
Why?
|
| Receptors, Vitronectin | 1 | 2007 | 8 | 0.080 |
Why?
|
| Young Adult | 5 | 2017 | 10793 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2012 | 503 | 0.080 |
Why?
|
| GTP-Binding Proteins | 2 | 2019 | 147 | 0.080 |
Why?
|
| Snake Venoms | 1 | 2007 | 17 | 0.080 |
Why?
|
| Transglutaminases | 2 | 2019 | 143 | 0.080 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2007 | 25 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 1158 | 0.080 |
Why?
|
| Inflammation | 1 | 2018 | 2566 | 0.080 |
Why?
|
| Prevalence | 4 | 2018 | 2326 | 0.080 |
Why?
|
| Age of Onset | 3 | 2017 | 467 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 1990 | 333 | 0.070 |
Why?
|
| Integrins | 1 | 2007 | 82 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2009 | 381 | 0.070 |
Why?
|
| Interleukin-2 | 3 | 2006 | 416 | 0.070 |
Why?
|
| Health Behavior | 1 | 2012 | 720 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 462 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2006 | 81 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 4552 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 1795 | 0.070 |
Why?
|
| Gene Expression | 3 | 2007 | 1489 | 0.070 |
Why?
|
| Signal Transduction | 4 | 2012 | 4709 | 0.070 |
Why?
|
| Coronary Disease | 1 | 1988 | 356 | 0.070 |
Why?
|
| Liver Neoplasms | 2 | 2012 | 527 | 0.070 |
Why?
|
| Registries | 3 | 2019 | 1810 | 0.070 |
Why?
|
| Infant, Newborn | 5 | 2012 | 5255 | 0.070 |
Why?
|
| Maternal Age | 1 | 2006 | 122 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 982 | 0.070 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2006 | 68 | 0.070 |
Why?
|
| Multigene Family | 1 | 2006 | 200 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2007 | 219 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 522 | 0.070 |
Why?
|
| ROC Curve | 2 | 2021 | 473 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 2092 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2008 | 445 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2005 | 67 | 0.070 |
Why?
|
| Parents | 1 | 2013 | 1212 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 642 | 0.060 |
Why?
|
| Life Style | 2 | 2020 | 430 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 301 | 0.060 |
Why?
|
| Herpes Genitalis | 1 | 2004 | 16 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 195 | 0.060 |
Why?
|
| Herpesvirus 2, Human | 1 | 2004 | 28 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 527 | 0.060 |
Why?
|
| Neoplasms | 2 | 2008 | 2179 | 0.060 |
Why?
|
| Social Workers | 1 | 2024 | 28 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2004 | 122 | 0.060 |
Why?
|
| Epithelium | 2 | 2018 | 305 | 0.060 |
Why?
|
| Gestational Age | 1 | 2006 | 765 | 0.060 |
Why?
|
| Genetic Linkage | 1 | 2003 | 321 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 260 | 0.060 |
Why?
|
| Proteome | 1 | 2006 | 353 | 0.050 |
Why?
|
| Nurse's Role | 1 | 2024 | 102 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 1308 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 462 | 0.050 |
Why?
|
| Linear Models | 2 | 2018 | 827 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 471 | 0.050 |
Why?
|
| Ligases | 1 | 2002 | 32 | 0.050 |
Why?
|
| Bradykinin | 1 | 2002 | 48 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2017 | 351 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2008 | 532 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2013 | 167 | 0.050 |
Why?
|
| Nurses | 1 | 2024 | 142 | 0.050 |
Why?
|
| Counseling | 1 | 2004 | 353 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2002 | 148 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2002 | 195 | 0.050 |
Why?
|
| Terminal Care | 1 | 2024 | 187 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 940 | 0.050 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2002 | 96 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2006 | 926 | 0.050 |
Why?
|
| Trauma Severity Indices | 2 | 2018 | 127 | 0.050 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 171 | 0.050 |
Why?
|
| Vaccines, DNA | 1 | 2000 | 32 | 0.050 |
Why?
|
| Angina Pectoris | 1 | 2020 | 63 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2000 | 47 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 770 | 0.050 |
Why?
|
| Free Radical Scavengers | 1 | 2020 | 88 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2024 | 482 | 0.050 |
Why?
|
| Disability Evaluation | 2 | 2012 | 280 | 0.050 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 45 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2002 | 272 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2006 | 652 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 289 | 0.050 |
Why?
|
| Optic Disk | 1 | 1999 | 36 | 0.040 |
Why?
|
| Papilledema | 1 | 1999 | 36 | 0.040 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2019 | 62 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 1999 | 53 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 242 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 2020 | 148 | 0.040 |
Why?
|
| Work Capacity Evaluation | 1 | 2018 | 13 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2019 | 85 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2000 | 238 | 0.040 |
Why?
|
| gamma Catenin | 1 | 2018 | 17 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 169 | 0.040 |
Why?
|
| Desmoglein 3 | 1 | 2018 | 17 | 0.040 |
Why?
|
| Metaplasia | 1 | 2018 | 57 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2000 | 267 | 0.040 |
Why?
|
| Bronchial Diseases | 1 | 2018 | 34 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2004 | 664 | 0.040 |
Why?
|
| Limb Salvage | 1 | 2018 | 52 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 87 | 0.040 |
Why?
|
| Time | 1 | 2018 | 77 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2020 | 237 | 0.040 |
Why?
|
| Thermodilution | 1 | 2017 | 13 | 0.040 |
Why?
|
| Tennessee | 1 | 2017 | 44 | 0.040 |
Why?
|
| Workload | 1 | 2018 | 128 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1691 | 0.040 |
Why?
|
| SEER Program | 2 | 2014 | 205 | 0.040 |
Why?
|
| Proteins | 1 | 2003 | 938 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2012 | 2657 | 0.040 |
Why?
|
| Industry | 1 | 2017 | 69 | 0.040 |
Why?
|
| Smokers | 1 | 2018 | 149 | 0.040 |
Why?
|
| HLA-DR4 Antigen | 1 | 2017 | 75 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1774 | 0.040 |
Why?
|
| HLA-DR3 Antigen | 1 | 2017 | 77 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2008 | 185 | 0.040 |
Why?
|
| Cytokines | 1 | 2005 | 1900 | 0.040 |
Why?
|
| Age Distribution | 1 | 2017 | 362 | 0.040 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 190 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 975 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 331 | 0.040 |
Why?
|
| Centrosome | 1 | 2016 | 59 | 0.030 |
Why?
|
| Community Health Centers | 1 | 1996 | 57 | 0.030 |
Why?
|
| Workplace | 1 | 2017 | 222 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2002 | 1055 | 0.030 |
Why?
|
| Cisplatin | 2 | 2007 | 271 | 0.030 |
Why?
|
| Dacarbazine | 2 | 2006 | 102 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 387 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2018 | 319 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 648 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 108 | 0.030 |
Why?
|
| Anxiety Disorders | 2 | 2006 | 309 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 2 | 2006 | 25 | 0.030 |
Why?
|
| Sample Size | 1 | 2015 | 133 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 124 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2018 | 277 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2012 | 671 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 164 | 0.030 |
Why?
|
| Marital Status | 1 | 2014 | 43 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 565 | 0.030 |
Why?
|
| Dabigatran | 1 | 2014 | 26 | 0.030 |
Why?
|
| Seat Belts | 1 | 1994 | 17 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2017 | 341 | 0.030 |
Why?
|
| Endoscopy | 1 | 2015 | 272 | 0.030 |
Why?
|
| HLA-DR2 Antigen | 1 | 2012 | 8 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2017 | 1003 | 0.030 |
Why?
|
| Protective Clothing | 1 | 2012 | 17 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 52 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 1994 | 178 | 0.030 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2012 | 43 | 0.030 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2012 | 61 | 0.030 |
Why?
|
| Placebos | 1 | 2012 | 202 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2012 | 89 | 0.030 |
Why?
|
| HLA-DRB1 Chains | 1 | 2012 | 97 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 161 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2014 | 262 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2011 | 7 | 0.030 |
Why?
|
| Skin Pigmentation | 1 | 2012 | 43 | 0.030 |
Why?
|
| Genes, ras | 1 | 2012 | 95 | 0.030 |
Why?
|
| Transcription Factors | 3 | 2006 | 1570 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 261 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 969 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 311 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2014 | 1293 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 41 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 317 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 516 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1384 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 1052 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 187 | 0.020 |
Why?
|
| Language | 1 | 2013 | 271 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 403 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 756 | 0.020 |
Why?
|
| Face | 1 | 2012 | 165 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 164 | 0.020 |
Why?
|
| HIV Infections | 1 | 2004 | 2459 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 468 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 872 | 0.020 |
Why?
|
| Cell Division | 2 | 2002 | 776 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 460 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 338 | 0.020 |
Why?
|
| Postural Balance | 1 | 2012 | 184 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 740 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2009 | 47 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 564 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 1194 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 296 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2009 | 63 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 942 | 0.020 |
Why?
|
| Body Composition | 1 | 2013 | 653 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 38 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 1990 | 368 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 245 | 0.020 |
Why?
|
| Capecitabine | 1 | 2008 | 46 | 0.020 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2008 | 12 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2009 | 333 | 0.020 |
Why?
|
| Pigmentation | 1 | 2009 | 58 | 0.020 |
Why?
|
| Mesoderm | 1 | 2009 | 141 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1203 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1988 | 124 | 0.020 |
Why?
|
| Health Surveys | 1 | 1990 | 454 | 0.020 |
Why?
|
| Polycomb-Group Proteins | 1 | 2008 | 36 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 66 | 0.020 |
Why?
|
| Walking | 1 | 2012 | 415 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 77 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2008 | 42 | 0.020 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2008 | 51 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2008 | 64 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1990 | 983 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2009 | 574 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2011 | 467 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 896 | 0.020 |
Why?
|
| Software | 1 | 2012 | 613 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2009 | 247 | 0.020 |
Why?
|
| Family Health | 1 | 2008 | 201 | 0.020 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2007 | 48 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 1988 | 162 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 1987 | 64 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2008 | 99 | 0.020 |
Why?
|
| Genome, Human | 1 | 2009 | 387 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2008 | 255 | 0.020 |
Why?
|
| Psychometrics | 1 | 1990 | 631 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 1987 | 125 | 0.020 |
Why?
|
| Vinblastine | 1 | 2006 | 68 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 180 | 0.020 |
Why?
|
| Diabetic Angiopathies | 1 | 2008 | 260 | 0.020 |
Why?
|
| Health Promotion | 1 | 2012 | 691 | 0.020 |
Why?
|
| Mice, Inbred A | 1 | 2005 | 45 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2005 | 36 | 0.020 |
Why?
|
| Calcinosis | 1 | 2008 | 282 | 0.020 |
Why?
|
| Energy Intake | 1 | 2008 | 447 | 0.020 |
Why?
|
| Antiemetics | 1 | 2005 | 34 | 0.020 |
Why?
|
| Melphalan | 1 | 2005 | 30 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2006 | 158 | 0.020 |
Why?
|
| Enzymes | 1 | 2005 | 66 | 0.020 |
Why?
|
| Carcinogens | 1 | 2005 | 108 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 1323 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2008 | 377 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 401 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 2005 | 15 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 381 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2006 | 191 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2006 | 119 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2005 | 120 | 0.020 |
Why?
|
| Trichomonas Infections | 1 | 2004 | 8 | 0.020 |
Why?
|
| Carboplatin | 1 | 2005 | 142 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 69 | 0.020 |
Why?
|
| Vaginosis, Bacterial | 1 | 2004 | 13 | 0.020 |
Why?
|
| Heart | 1 | 1988 | 631 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 1166 | 0.020 |
Why?
|
| Species Specificity | 1 | 2005 | 565 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 143 | 0.020 |
Why?
|
| DNA Replication | 1 | 2005 | 211 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2004 | 267 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2003 | 18 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2006 | 200 | 0.020 |
Why?
|
| Genomics | 1 | 2009 | 706 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2004 | 146 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2062 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2003 | 25 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 333 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2003 | 30 | 0.020 |
Why?
|
| Adult Children | 1 | 2003 | 18 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2003 | 63 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 597 | 0.010 |
Why?
|
| Condoms | 1 | 2004 | 110 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 74 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2003 | 65 | 0.010 |
Why?
|
| Lithium | 1 | 2003 | 41 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 888 | 0.010 |
Why?
|
| Air Pollutants | 1 | 1987 | 316 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 180 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2003 | 83 | 0.010 |
Why?
|
| Fetus | 1 | 1987 | 690 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2005 | 367 | 0.010 |
Why?
|
| Risk Reduction Behavior | 1 | 2004 | 199 | 0.010 |
Why?
|
| COP9 Signalosome Complex | 1 | 2002 | 6 | 0.010 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2002 | 11 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 510 | 0.010 |
Why?
|
| Pedigree | 1 | 2003 | 485 | 0.010 |
Why?
|
| Wnt Proteins | 1 | 2003 | 140 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2002 | 18 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2004 | 175 | 0.010 |
Why?
|
| Rats, Nude | 1 | 2002 | 27 | 0.010 |
Why?
|
| Wings, Animal | 1 | 2002 | 33 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 141 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 77 | 0.010 |
Why?
|
| COS Cells | 1 | 2002 | 184 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2004 | 299 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 732 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 2002 | 35 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2002 | 98 | 0.010 |
Why?
|
| Dimerization | 1 | 2002 | 183 | 0.010 |
Why?
|
| Histone Deacetylases | 1 | 2003 | 198 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 155 | 0.010 |
Why?
|
| Thiazoles | 1 | 2002 | 121 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2002 | 108 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2002 | 305 | 0.010 |
Why?
|
| Pregnancy | 2 | 1990 | 5690 | 0.010 |
Why?
|
| Drosophila | 1 | 2002 | 140 | 0.010 |
Why?
|
| Health Status | 1 | 2006 | 726 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 298 | 0.010 |
Why?
|
| Superantigens | 1 | 2000 | 68 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2005 | 922 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2002 | 133 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 367 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 828 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 2002 | 241 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 174 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 1180 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 736 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 823 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 404 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2002 | 356 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 291 | 0.010 |
Why?
|
| Alcoholism | 1 | 2006 | 717 | 0.010 |
Why?
|
| Plasmids | 1 | 2000 | 355 | 0.010 |
Why?
|
| Graft Survival | 1 | 2002 | 504 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2002 | 749 | 0.010 |
Why?
|
| HIV-1 | 1 | 2004 | 776 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 155 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 334 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 1353 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 1323 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2006 | 971 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 2871 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1816 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 2707 | 0.010 |
Why?
|
| Neutrophils | 1 | 2002 | 1233 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 3730 | 0.010 |
Why?
|
| Calcium | 1 | 2002 | 1169 | 0.010 |
Why?
|
| Aging | 1 | 2006 | 1670 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1346 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1994 | 39 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 182 | 0.010 |
Why?
|
| Urban Population | 1 | 1996 | 409 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 5392 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 1129 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1994 | 394 | 0.010 |
Why?
|